Table 4. Summary of Regression Analyses Predicting EBV and CMV Antibody Titers.
| EBV (log10) | CMV (log10) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Model | Variable | B | SE | p | 95% CI | B | SE | p | 95% CI |
| Step 1 | Age | .00 | .00 | .98 | -.01, .01 | .01 | .01 | .27 | -.01, .02 |
| BMI | .00 | .01 | .53 | -.01, .02 | .01 | .01 | .20 | -.01, .04 | |
| Cancer Stage | .03 | .03 | .40 | -.04, .10 | .02 | .06 | .68 | -.10, .14 | |
| Months since treatment | -.01 | .01 | .01 | -.02, -.003 | -.02 | .01 | .03 | -.03, -.002 | |
| Comorbidities | .03 | .11 | .82 | -.20, .25 | -.01 | .20 | .95 | -.42, .39 | |
| Weekly alcohol consumption | -.01 | .01 | .63 | -.03, .02 | -.00 | .20 | .90 | -.04, .03 | |
| Sleep | .01 | .01 | .40 | -.01, .03 | .02 | .02 | .35 | -.02, .05 | |
| r | .30 | .39 | |||||||
| F | 1.33 | .25 | 1.25 | ||||||
| Df | (7, 96) | (7, 48) | .30 | ||||||
|
| |||||||||
| Step 2 | Age | .00 | .00 | .75 | -.01, .01 | .01 | .01 | .38 | -.01, .02 |
| BMI | .01 | .01 | .30 | -.01, .02 | .02 | .01 | .07 | -.002, .04 | |
| Cancer Stage | .04 | .03 | .22 | -.03, .11 | .06 | .06 | .28 | -.05, .18 | |
| Months since treatment | -.01 | .01 | .01 | -.02, -.004 | -.02 | .01 | .02 | -.03, -.002 | |
| Comorbidities | .04 | .11 | .71 | -.18, .26 | .08 | .20 | .70 | -.32, .47 | |
| Weekly alcohol consumption | .00 | .01 | .92 | -.02, .02 | .01 | .02 | .73 | -.03, .04 | |
| Sleep | .00 | .01 | .84 | -.02, .02 | -.00 | .02 | .91 | -.04, .04 | |
| Childhood Adversities | .09 | .04 | .02 | .01, .16 | .15 | .07 | .03 | .01, .28 | |
| Δ r | .08 | .09 | |||||||
| F Δ | 5.54 | .02 | 4.77 | ||||||
| Δdf | 1 | 1 | 1 | ||||||